AptarGroup, Inc.
HealthcareNYSE:ATR · New York Stock Exchange
+$1.14 today
Vol 0.26M · Avg 0.52M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.7%
avg 14.4%
ROIC
9.2%
avg 8.8%
ROA
7.5%
avg 6.8%
Analysis
ROE is currently the strongest return metric at 14.7% versus its period average of 14.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stephan Tanda | President, Chief Executive Officer & Executive Director | $1.75M | — | 61 | $254,267.00 | 0.40% |
Gael Touya | President of Aptar Pharma | $1.62M | — | 56 | $37,017.00 | 0.06% |
Hedi Tlili | President of Aptar Closures | $1.10M | — | 51 | $24,233.00 | 0.04% |
Vanessa Kanu | Executive Vice President & Chief Financial Officer | $1.06M | — | 48 | $24,646.00 | 0.04% |
Xiangwei Gong | Executive VP of Strategic Group Development & President of Aptar Asia | $1.06M | — | 56 | $10,774.00 | 0.02% |
Marc Prieur | President of Aptar Beauty | $964,014.00 | — | 60 | $19,770.00 | 0.03% |
Irene Hudson | Executive Vice President, Chief Legal Officer & Corporate Secretary | — | — | 49 | $1,480.00 | <0.01% |
Mary Skafidas | Senior Vice President of Investor Relations & Communications | — | — | — | — | — |
Daniel Richard Ackerman | Senior VP, Principal Accounting Officer & Chief Accounting Officer | — | — | 53 | $32,779.00 | 0.05% |
Alex Theodorakis | Head of Pharma Prescription | — | — | — | — | — |
Shiela Pallerne Vinczeller | Chief Human Resources Officer | — | — | 62 | $27,291.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$5.02M
Net Sentiment
$5.02M
Net selling
Most Active
Prieur Marc
4 transactions
1–10 of 15
Analysis
Insiders reported 0 buys worth $0.00 and 15 sells worth $5.02M over the last 12 months. That adds up to net selling of $5.02M. Prieur Marc was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +9.1% | +6.6% (13yr)2 analysts |
| Revenue | N/A | N/A | -0.2% | +5.1% (13yr)3 analysts |
| Net Income | N/A | N/A | +7.0% | +6.9% (13yr)3 analysts |
| EBIT | N/A | N/A | +7.8% | +4.1% (13yr)3 analysts |
Analysis
Recent growth has been strongest in EPS at +9.1% over three years. Forward estimates point to Net Income at +6.9% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Globus Medical, Inc.
NYSE:GMED
$10.86B
Molina Healthcare, Inc.
NYSE:MOH
$10.44B
Masimo Corporation
NASDAQ:MASI
$9.42B
Henry Schein, Inc.
NASDAQ:HSIC
$9.31B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.26B
Repligen Corporation
NASDAQ:RGEN
$7.46B
Grifols, S.A.
NASDAQ:GRFS
$6.49B
Avantor, Inc.
NYSE:AVTR
$6.47B
Teleflex Incorporated
NYSE:TFX
$5.78B
Stevanato Group S.p.A.
NYSE:STVN
$4.65B
Who manages ATR?
AptarGroup, Inc. (ATR) lists 11 active executives. The top listed executive is Gael Touya, President of Aptar Pharma.
Are ATR insiders buying or selling?
Recent insider activity shows net selling of $4.98M.
Explore More
Continue the stock analysis
Jump to another research area for this company.